Skip to main content

The CTD² Network and Cancer Systems Biology Consortium organized a virtual symposium series titled “Multidisciplinary Approaches to Understand Cancer Treatment Resistance”. Please join us on 11/16, 11/17, 12/2, 12/16, and 12/17. Click here to view the registration website.

Publications

644 Publications Available
Cell Reports

The findings presented in this manuscript establish CTCF as a prominent tumor-suppressor gene and point to CTCF-mediated epigenetic stability as a major barrier to neoplastic progression.

Cell

Researchers elucidate endogenous barriers limiting the process of reprogramming somatic cells to induced pluripotent stem cells by systematically dissecting human cellular reprogramming.

CNS Oncology

Researchers discuss the development of effective targeted therapy to manage Group 3 medulloblastomas by targeting α5-GABA-A receptor.

Cell

The transcriptional coactivator YAP1 rescued cell viability in KRAS-dependent cells upon suppression of KRAS and was required for KRAS-induced cell transformation. 

Blood

Investigators find that acute myeloid leukemias with MLL fusions are dependent on CDK6, offering a therapeutic strategy.

Nature Medicine

BET proteins are critical regulators of the Hedgehog pathway, suggesting that BET inhibitors may be used to treat Hedgehog-driven tumors.

Nucleic Acids Research

Authors develop a computational approach for automated quantitation of off-target effects in RNAi screening data sets.

Methods in Molecular Biology

Researchers present methods which are specifically designed to handle cancer-related copy-number profiles.

Cancer Research

In an effort to identify biomarkers of recurrence for Prostate cancer, researchers performed global RNA sequencing on 106 formalin-fixed, paraffin-embedded prostatectomy samples from 100 patients at three independent sites, defining a 24-gene signature panel.

Nature Communications

Researchers use reverse-phase protein arrays to study the proteome and compare it to the genomic and transcriptome analysis of 11 TCGA pan-cancer diseases.